EMERGING INSIGHTS More Aggressive LDL-C Target May Be Better +++++

More Aggressive LDL-C Target May Be Better for Secondary CV Prevention: Ez-PAVE Brian Owens https://www.medscape.com/viewarticle/more-aggressive-ldl-c-target-may-be-better-secondary-cv-2026a1000bkk?ecd=mkm_ret_260517_mscpmrk_cardio_lipids_mai_etid8346155&uac=148436CN&impID=8346155 April 14, 2026 More intensive use of lipid-lowering drugs to reach a lower target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular (CV) events by one third among people with atherosclerotic CV disease (ASCVD), according to a study in South Korea. AI Tool Predicts LDL Without Direct Testing Becky McCall, PhD, MScPh https://www.medscape.com/viewarticle/ai-tool-predicts-ldl-without-direct-testing-2026a10009q1?ecd=mkm_ret_260517_mscpmrk_cardio_lipids_mai_etid8346155&uac=148436CN&impID=8346155 Medscape Europe March 31, 2026 VIENNA — A machine learning model using routinely collected laboratory parameters estimates low-density lipoprotein cholesterol (LDL-C) with reasonable accuracy, potentially offering a practical and low-cost approach to cardiovascular risk screening. Why ‘Normal’ LDL Cholesterol May Not Be Safe for Future Moms Kaitlin Sullivan https://www.medscape.com/viewarticle/why-normal-ldl-cholesterol-may-not-be-safe-future-moms-2026a1000eaj?ecd=mkm_ret_260517_mscpmrk_cardio_lipids_mai_etid8346155&uac=148436CN&impID=8346155 May 05, 2026 Women with prepregnancy biomarkers for lipids in the higher end of the “normal” range faced higher odds of developing hypertensive disorders of pregnancy, according to a study published in JAMA Network Open. Follow-Up Lipid Testing and Statin Initiation Among Young Adults in a U.S. Health Care System Teresa N. Harrison, SM; Yiyi Zhang, PHD; Soon Kyu Choi, MSC; Katherine J. Pak, MPH; Hui Zhou, PHD; Kerresa Morrissette, MPH; Kristi Reynolds, PHD; Ronald D. Scott, MD; Jaejin An, PHD https://www.medscape.com/s/viewarticle/follow-lipid-testing-and-statin-initiation-among-young-2026a1000d42?ecd=mkm_ret_260517_mscpmrk_cardio_lipids_mai_etid8346155&uac=148436CN&impID=8346155#1 Abstract BACKGROUND: More than 50% of U.S. young adults have low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dL, and young adults are less likely to be aware of their high LDL-C levels compared with older age adults. MHRA Approves Olezarsen for Rare Lipid Disorder Dr Rob Hicks https://www.medscape.com/s/viewarticle/follow-lipid-testing-and-statin-initiation-among-young-2026a1000d42?ecd=mkm_ret_260517_mscpmrk_cardio_lipids_mai_etid8346155&uac=148436CN&impID=8346155#1 Medscape UK April 13, 2026 Adults with familial chylomicronaemia syndrome (FCS) — a rare inherited condition that can cause life-threatening pancreatic inflammation — are a step closer to a new treatment option following approval of olezarsen (Tryngolza, Ionis Pharmaceuticals) by the Medicines and Healthcare products Regulatory Agency (MHRA).